Nashville, TN and Seattle, WA – May 14, 2026 – Azra AI, the leading end-to-end enterprise platform for incidental findings and oncology workflow automation, and RevealDx, the leader in AI tools for the characterization of lung nodules, today announced a new partnership. This partnership builds upon Azra AI’s recent acquisition of Thynk health, which provides … Azra and RevealDx Announce Partnership
News
Seattle, WA – February 3, 2026 – RevealDx, a leader in AI tools for the characterization of lung nodules, announced FDA clearance of RevealAI-Lung. The company had previously announced MDR Certification in November of 2025. The RevealDx technology characterizes incidental lung nodules by producing a Malignancy Similarity Index (mSI™), a score that is intended to … RevealDx Receives FDA Clearance for AI Powered Lung Nodule Risk Assessment
RDX clinical radiology pub
RevealDx MDR Announcement FINAL.docx
Seattle, WA and Miamisburg, OH – October 3, 2024 – RevealDx and Riverain Technologies, leaders in the detection and characterization of lung nodules, announced the integration of their products, as well as distribution by Riverain in Canada. Both companies will be exhibiting at the CHEST Meeting beginning October 7, 2024. The RevealDX technology characterizes nodules … RevealDx and Riverain Technologies Partner to Improve Lung Cancer Detection with mSI Malignancy Scoring